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A B S T R A C T
Purpose
Human papillomavirus (HPV) type 16 (HPV16) causes cancer at several anatomic sites. In the European
Prospective Investigation Into Cancer and Nutrition study, HPV16 E6 seropositivity was present more than
10 years before oropharyngeal cancer diagnosis and was nearly absent in controls. The current study
sought to evaluate the extent to which HPV16 E6 antibodies are present before diagnosis of anogenital
cancers within the same cohort.
Methods
Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile
cancers) with prediagnostic blood samples (collected on average 3 and 8 years before diagnosis
for cervix and noncervix cancers, respectively) and 718 matched controls were included. Plasma
was analyzed for antibodies against HPV16 E6 and multiple other HPV proteins and genotypes and
evaluated in relation to risk using unconditional logistic regression.
Results
HPV16 E6 seropositivity was present in 29.2% of individuals (seven of 24 individuals) who later
developed anal cancer compared with 0.6% of controls (four of 718 controls) who remained
cancer free (odds ratio [OR], 75.9; 95% CI, 17.9 to 321). HPV16 E6 seropositivity was less
common for cancers of the cervix (3.3%), vagina (8.3%), vulva (1.5%), and penis (8.3%). No
associations were seen for non–type 16 HPV E6 antibodies, apart from anti-HPV58 E6 and anal
cancer (OR, 6.8; 95% CI, 1.4 to 33.1). HPV16 E6 seropositivity tended to increase in blood samples
drawn closer in time to cancer diagnosis.
Conclusion
HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other
HPV-related anogenital cancers.
J Clin Oncol 33:877-884. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Human papillomavirus (HPV) type 16 (HPV16)
causes approximately 50% of cervical cancers, 80% of
anal cancers, and roughly half of vaginal, vulvar, and
penile cancers worldwide.1-5 The fraction of oropha-
ryngeal cancers (OPCs) caused by HPV16 varies
greatly by geographic region; approximately 60% to
70% of OPCs in some developed countries are caused
by HPV16 compared with a much smaller proportion
( 10%) in developing countries.6-10 Recently, we re-
portedthatpatientswithHPV16E6seropositivitywere
at greater than 200-fold increased risk of OPC, and
these antibodies were present up to 10 years before
diagnosis, while being extremely rare among cancer-
free controls.11 These results were noteworthy because
theysuggestthatitmightbepossibletodevelopahighly
specific biomarker for HPV-driven OPC that may be
useful for screening,12 at least if the current OPC inci-
dence trends continue to increase.6
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Previous case-control studies have reported associations between
HPV16 E6 seropositivity and anogenital cancers, specifically among
cancers of the uterine cervix13-17 and penis18; these studies were retro-
spective, with blood samples collected at the time of diagnosis. Three
prospective studies on HPV16 E6 seropositivity and anogenital cancer
have been conducted to date, two for cervical cancer19,20 and one for
anal cancer.21 These studies identified associations between HPV16 E6
seropositivity and cancer development, with seropositivity more fre-
quently detected a few years before diagnosis. We aimed to clarify the
association between HPV16 E6 antibody positivity and risk of ano-
genital cancers, including incident cervical, anal, penile, vulvar, and
vaginal cancers, within the European Prospective Investigation Into
Cancer and Nutrition (EPIC) study.22
METHODS
Study Cohort
The EPIC cohort was designed to investigate the relationship between
nutritional and lifestyle factors and incidence of cancer and other chronic
diseases.22 Questionnaire data were collected between 1992 and 2000 from
521,330 individuals across Europe, of whom 385,747 provided a blood sample.
All participants gave written informed consent, and the research was approved
by the local ethics committees and the International Agency for Research on
Cancer Institutional Review Board.
Follow-Up for Cancer Incidence
Incident cancers were identified through population-based cancer regis-
tries (Denmark, Italy [except Naples], the Netherlands, Norway, Spain, Swe-
den, and the United Kingdom) or by active follow-up (France, Germany,
Greece, and Naples). Active follow-up involved a combination of methods,
including review of health insurance records and cancer and pathology regis-
tries, as well as direct contact with participants and their next of kin.
Selection of Patient Cases and Controls
We identified 1,829 patients with histologically confirmed anogenital
cancer without a history of another cancer (except nonmelanoma skin cancer),
defined using the International Classification of Diseases for Oncology, Sec-
ond Edition (ICD-O-2), including invasive cancer of the cervix uteri (ICD-
O-2 C53.0 to C53.9), anus (ICD-O-2 C21.1), vulva (ICD-O-2 C51.0 to C51.9),
vagina (ICD-O-2 C52.9), and penis (ICD-O-2 C60.0 to C60.9). After exclud-
ing prevalent patients (n  122), patients without available blood samples
(n  893), patients without baseline questionnaire (n  1), and patients from
three centers that did not participate in the current study (Copenhagen, Århus,
and Malmö, n  253), 560 eligible patients remained. We included all eligible
patients with noncervical anogenital cancer (n  127), including 24 anal
cancers, 67 vulvar cancers, 12 vaginal cancers, and 24 penile cancers. Many
more eligible patients with cervical cancer were available than for the other
cancer sites (n  443), and because previous studies18,19 indicated that HPV
seroconversion occurred closer to diagnosis for cervical cancer, we selected a
subset of 200 patients by oversampling among those with shorter time from
blood draw to diagnosis (lead time). The final study population also included
all additional eligible cervical cancers from the Swedish Umeå center (n  73),
adding up to a total of 273 cervical cancers, 34 with a lead time between 0
and less than 1 year (navailable  59), 52 with a lead time between 1 and less
than 2 years (navailable  61), 99 with a lead time between 2 and less than 5
years (navailable  171), 71 with a lead time between 5 and less than 10 years
(navailable  152), and 17 with a lead time of  10 years (navailable  42).
For each patient case, two controls were randomly chosen from appro-
priate risk sets consisting of all cohort members alive and free of cancer (except
nonmelanoma skin cancer) at the time (and hence age) of diagnosis of the
index patient case. Matching criteria included study center, sex, date of blood
collection ( 3 months, relaxed to  6 months for sets without available
controls), age at blood collection ( 3 months, relaxed to  2 years for sets
without available controls), fasting status, and where relevant, menopausal
status, postmenopausal hormone replacement therapy use, and menstrual
cycle. The final study population included a total of 273 patients with cervical
cancer and 127 patients with noncervical cancer, along with 718 controls.
Serologic Analyses
Plasma samples were sent on dry ice to the German Cancer Research
Center (Heidelberg, Germany) and stored at 20°C until analysis. Testing was
performed using multiplex assays23,24 by laboratory staff blinded to the case-
control status of the participants. Antigens were affinity-purified, bacterially
expressed fusion proteins with N-terminal glutathione S-transferase. Samples
were analyzed for antibodies to the major capsid protein (L1), the early onco-
proteins (E6 and E7), and other early proteins (E1, E2, and E4) of the following
carcinogenic mucosal types: HPV16 and HPV18 (L1, E1, E2, E4, E6, and E7)
and HPV31, HPV33, HPV45, and HPV52 (L1, E6, and E7). We also analyzed
the noncarcinogenic mucosal types HPV6 and HPV11 (L1, E6, and E7). We
used the same median fluorescence intensity (MFI) cutoffs as in our previous
analysis when defining HPV-seropositive patients.11 A subset of samples were
randomly chosen and included as blinded duplicates; intraclass correlation
coefficients ranged from 95% to 98%, and coefficients of variation were less
than 5%.
Statistical Analyses
Characteristics of the patients with cancer (by anatomic site of the can-
cer) and controls were tabulated. Odds ratios (ORs) and 95% CIs were calcu-
lated by anatomic site using unconditional logistic regression (because few
controls were seropositive for some markers, the final risk analysis included all
controls to allow calculation of the OR). Covariates in the models comprised
the following matching factors: country (North v South Europe, where north-
ern Europe included Denmark, Germany, Great Britain, the Netherlands, and
Sweden and southern Europe included France, Greece, Italy, and Spain), sex
(for anal cancer, the only anatomic site that occurs in both sexes), and age (as
a continuous variable). Additional adjustment by tobacco did not meaning-
fully affect the point estimates. Further statistical adjustment was not possible
because of the limited sample numbers and rarity of HPV16 E6–positive
patients and controls. MFI values were evaluated among HPV16 E6–positive
individuals. Data on cancer stage were only available for approximately 40% of
patients and were not considered in the analysis.
In our previous work,11 higher specificity was achieved without loss of
sensitivity when applying a more stringent threshold for HPV16 E6 seroposi-
tivity. Thus, we similarly evaluated the validity in prediction of anogenital




From the EPIC cohort, incident cervical (n273), anal (n24),
vulvar (n  67), vaginal (n  12), and penile (n  24) cancers and 718
cancer-free individuals were included (Table 1). The patients with
cancer were generally representative of those not included with respect
to age, sex (anal cancer only), smoking, and education (Appendix
Table A1, online only). Of the patients with anal cancer (the only
cancer site under study that occurred in both sexes), 87.5% were
women. Among patient cases, median age at diagnosis was younger
for patients with cancer of the cervix (43.0 years) compared with
patients with cancers of the anus (61.0 years), vagina/vulva (65.0
years), and penis (63.5 years). The median time between blood
draw and diagnosis (lead time) ranged from 7 to 8 years for the
noncervix cancer sites. Because patients with cervical cancer with
shorter lead time were oversampled, the median lead time for
cervical cancer was 3 years.
Kreimer et al
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HPV16 Seropositivity and Cancer Risk
Seropositivity against HPV16 E6 was most frequent in prediag-
nostic plasma from patients with anal cancer (seven of 24 patients;
29.2%; Table 2). HPV16 E6 seroprevalence was substantially lower in
all other anogenital cancers, including cancer of the cervix (nine of 274
patients; 3.3%), penis (two of 24 patients; 8.3%), vagina (one of 12
patients; 8.3%), and vulva (one of 67 patients; 1.5%). The anatomic
subsites of the HPV16 E6–seropositive penile cancers were prepuce
(ICD-O-2 C60.0) and glans penis (ICD-O-2 C60.1), and the vulvar
cancer was vulva, not otherwise specified (ICD-O-2 C51.9). HPV16
E6 seropositivity was extremely rare in cancer-free individuals (four of
718 individuals; 0.6%; Table 2).
Of the six HPV16 proteins evaluated, E6 was most strongly asso-
ciated with all anogenital cancer sites; anal cancer displayed the stron-
gest association, with an OR of 75.9 (95% CI, 17.9 to 321), followed by
vaginal cancer, with an OR of 24.1 (95% CI, 2.1 to 277), and cervical
cancer, with an OR of 9.5 (95% CI, 2.4 to 37.1). Similarly, HPV16 L1
seropositivity was also associated with risk of anal (OR, 11.0; 95% CI,
4.7 to 25.7), vulvar (OR, 3.4; 95% CI, 1.8 to 6.4), and cervical (OR, 2.9;
95% CI, 1.9 to 4.2) cancers. Risk of anal cancer was elevated for most of
the HPV16 proteins, in contrast to the other anatomic sites; beyond E6
and L1, an increased risk of anal cancer was observed for HPV16 E7
(OR, 7.3; 95% CI, 2.9 to 18.4) and E1 (OR, 4.5; 95% CI, 1.6 to 12.8)
seropositivity, but not for E2 or E4 (Table 2). All seven of the HPV16
E6 seropositive anal cancers occurred among women (n  21; HPV16
E6 seroprevalence among women with anal cancer was 33.3%); none
of the three men with anal cancer had HPV16 E6 seropositivity. No
differences were seen between HPV16 E6–positive and –negative anal
cancers by other variables (including age at diagnosis, region of Eu-
rope [south v north], smoking or drinking status, or body mass index;
data not shown).
In the sensitivity analysis using the more stringent definition
of HPV16 E6 seropositivity (MFI, 1,000), all of the HPV16 E6 –
seropositive anal, vaginal, and vulvar cancers (using the lower
threshold) remained positive, whereas seven of the nine cervical
cancers, one of the two penile cancers, and one of the four controls
remained positive at the higher threshold.
MFI values were evaluated among HPV16 E6–positive individ-
uals. HPV16 E6–seropositive controls seemed to have lower median
values (MFI, 788) than did HPV16 E6–seropositive patients with anal
(MFI, 2,694), cervical (MFI, 3,400), vaginal (MFI, 5,761), and vulvar
(MFI, 1,914) cancer, but not penile cancer (MFI, 970).
HPV16 E6 Seropositivity and Time to Diagnosis
of Cancer
HPV16 E6 seropositivity and cancer risk were evaluated in two
strata defined by lead time between blood collection and cancer diag-
nosis ( or  5 years; Table 3). Of the eight anal cancers diagnosed in
the interval with less than 5 years between blood draw and diagnosis,
62.5% (n  5) were HPV16 E6 seropositive, whereas of the 16 anal



















No. % No. % No. % No. % No. % No. % No. %
Sex
Male 60 100 0 0 0 0 3 12.5 24 100 0 0 0 0
Female 0 0 658 100 273 100 21 87.5 0 0 12 100 67 100
Age, years
 40 2 3.3 248 37.7 166 60.8 3 12.5 1 4.2 1 8.3 6 9.0
41-50 17 28.3 167 25.4 66 24.2 7 29.2 7 29.2 3 25.0 10 14.9
51-60 21 35.0 133 20.2 28 10.3 5 20.8 9 37.5 5 41.7 26 38.8
61-70 16 26.7 97 14.7 11 4.0 8 33.3 5 20.8 3 25.0 23 34.3
 70 4 6.7 13 2.0 2 0.7 1 4.2 2 8.3 0 0 2 3.0
Country
France 0 0 10 1.5 0 0 2 8.3 0 0 0 0 1 1.5
Germany 20 33.3 154 23.4 45 16.5 9 37.5 7 29.2 6 50.0 12 17.9
Great Britain 16 26.7 138 21.0 49 17.9 5 20.8 5 20.8 0 0 13 19.4
Greece 4 6.7 40 6.1 10 3.7 0 0 2 8.3 1 8.3 7 10.5
Italy 6 10.0 62 9.4 18 6.6 3 12.5 2 8.3 1 8.3 7 10.5
The Netherlands 2 3.3 52 7.9 5 1.8 1 4.2 1 4.2 1 8.3 17 25.4
Norway 0 0 12 1.8 2 0.7 0 0 0 0 1 8.3 2 3.0
Spain 8 13.3 57 8.7 22 8.1 0 0 4 16.7 1 8.3 5 7.5
Sweden 4 6.7 134 20.2 122 44.7 4 16.7 3 12.5 1 8.3 3 4.5
Smoking
Never 18 30.0 391 59.4 127 46.5 12 50.0 8 33.3 10 83.3 36 53.7
Former 29 48.3 136 20.7 59 21.6 6 25.0 8 33.3 1 8.3 14 20.9
Current 13 21.7 121 18.4 83 30.4 4 16.7 8 33.3 1 8.3 17 25.4
Education
Primary 17 28.3 216 32.9 54 19.8 11 45.8 10 41.7 6 50.0 32 47.8
 Primary school 43 71.7 434 66.0 216 79.1 11 45.8 14 58.3 6 50.0 35 52.2
NOTE. All variables were assessed at enrollment. Percentages do not add to 100% as a result of missing data.
HPV16 E6 and Risk of Anogenital Cancer


















































































































































































































































































































































































































































































































































































































































































































































































880 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
cancers diagnosed with a longer lead time, only 12.5% (n  2) were
HPV16 E6 seropositive. For patients with cervical cancer, HPV16 E6
seropositivity was more common with the shorter lead time (eight of
185 patients; 4.3%) versus the longer lead time (one of 88 patients;
1.1%). When the shorter interval was further stratified for cervical
cancer (the only site with sufficient sample size), HPV16 E6 seropos-
itivity increased the closer in time to cancer diagnosis, being 8.8%
(three of 34 patients), 3.8% (two of 52 patients), and 3.0% (three of 99
patients) for 0 to less than 1, 1 to less than 2, and 2 to less than 5 years
before diagnosis, respectively.
Non–Type 16 HPV E6 Seropositivity and Cancer Risk
Among the non-HPV16 E6 proteins, associations between
HPV33 and HPV58 and anal cancer were observed; the odds increased
17-fold (95% CI, 3.9 to 79.2) for HPV33 and seven-fold (95% CI, 1.9
to 27.7) for HPV58 (Table 4). Because these HPV types are phyloge-
netically related to HPV16, these associations were further analyzed
restricted to patients with anal cancer and controls who were HPV16
E6 seronegative to eliminate any effects caused by antibody cross-
reactivity13; the significant association persisted for HPV58 (OR, 6.8;
95% CI, 1.4 to 33.1) but not for HPV33 (OR, 7.4; 95% CI, 0.8 to 67.2).
No clear associations were observed for cervical cancer and non-16
HPV types (Table 4).
DISCUSSION
In this comprehensive analysis of HPV-related anogenital cancers,
we observed that HPV16 E6 seropositivity was common in patients
who later developed anal cancer. For anal cancer, 29% of patients
and 0.6% of controls were seropositive for HPV16 E6, correspond-
ing to a 75-fold risk increase in HPV16 E6 –seropositive versus–
seronegative individuals. We also observed increased risk among
HPV16 E6 –seropositive individuals for cancers of the vagina, cer-
vix, and penis, but the magnitude of the associations was not nearly
as strong as for anal cancer.
Few studies have prospectively investigated HPV16 E6 and risk of
anogenital cancer. One study of cervical cancer (median follow-up
time, 3.5 years) showed that 4% of patients had prediagnostic antibod-
ies to the HPV16/18 E6 or E7 proteins compared with 1.2% of con-
trols. Increased risk was only evident for cervical cancer diagnosed
within approximately 3 years of blood draw.19 In a more recent study,
Castellsagué et al20 observed that 11% of incident invasive cervical
cancers from EPIC (a subset [n  60, 22%] of the patients in the
current analysis) were HPV16 E6 seropositive compared with 1.4% of
controls. The proportions seropositive were higher than what were
observed in the current analysis (patients, 3.3%; controls, 0.6%), but
the magnitude of the association was similar, suggesting that a more
stringent threshold for positivity was used in the current analysis.
Furthermore, HPV16 E6 seroprevalence further increased in those
with shorter time between blood draw and diagnosis, with 9% of
cervical cancers diagnosed within a year of blood draw being HPV16
E6 seropositive. For anal cancer, Bertisch et al21 showed that 22% of
incident anal cancers among HIV-positive individuals had prediag-
nostic HPV16 E6 seropositivity, a result that would seem consistent
with our overall estimate of 29%; yet in our samples taken closer to
diagnosis ( 5 years; Table 3), a notably higher fraction were positive.
The observed strong association between HPV16 E6 serology
and anal cancer should be interpreted in the context of our previous
study on head and neck cancer within the same cohort,11 as well as the
published literature. During the period of time of the EPIC study
(1990s to 2000s), a notably higher fraction of anal cancers (approxi-
mately 63%)5 than OPCs (approximately 35%)25 were likely caused
by HPV16 infection. Thirty-five percent of OPCs in our previous
study were HPV16 E6 seropositive11; these data suggest that the vast
majority of HPV-driven OPCs were identified in the prediagnostic
sera. In contrast, only 29% of incident anal cancers were HPV16 E6
seropositive in EPIC, which is a notably lower fraction than observed
in previous studies of HPV16 DNA tumor prevalence in anal cancer.5
We interpret this to mean that the vast majority of HPV-driven OPCs
seroconvert well before clinical manifestation, whereas some, but not
all, anal cancers do, and that HPV serology would be more sensitive for
detection of HPV-driven OPC than for HPV-driven anal cancer. In
support of this, we also noted that most of the HPV16 E6–seropositive
anal cancers were diagnosed less than 5 years after blood draw,
whereas the fraction of seropositive OPCs was stable over the  10-
year follow-up period.11
Our results further indicate that a preclinical antibody response is
mostly lacking for patients with cervical, penile, vaginal, and vulvar
cancer when assessed within the same cohort using the same labora-
tory and assay for serologic testing. A recent cross-sectional study
demonstrated that, for cervical cancer, HPV16 E6 seropositivity at
time of diagnosis was 32% among all invasive cervical cancers (and
50% among HPV16 DNA–positive invasive cervical cancers)12; HPV
E6 and E7 antibodies may be late tumor markers that increase with
clinical tumor stage.14,15,17 Our limited data on cervical cancers diag-
nosed shortly after blood draw also suggested a higher HPV16 sero-
prevalence immediately preceding diagnosis, which decreases as one
moves further from diagnosis (8.8% in the year preceding diagnosis;
3.8% in blood collected 1 to 2 years before diagnosis), again highlight-
ing differences in the immune response by anatomic site.


























No. % No. % No. % No. % No. %
 5 185 8 4.3 8 5 62.5 7 1 14.2 4 0 0 21 1 4.7
 5 88 1 1.1 16 2 12.5 17 1 5.8 8 1 12.5 46 0 0
Abbreviation: HPV16, human papillomavirus type 16.
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It is presently unclear why the associations between HPV16 E6
and cancer differ by anatomic site, but the immunobiology and prox-
imity to the lymphatic system (and thus access to antigen-presenting
cells) are likely important. The tonsil is a lymphoid organ rich in
immune cells including antibody-producing B cells. Similarly, in the
anus, HPV infection occurs at the dentate (pectinate) line or transfor-
mation zone of squamous and nonsquamous mucosa. This site is in
close proximity to the secondary lymphoid tissue of the GI tract
including Peyer’s, cecal, and rectal patches, as well as isolated lym-
phoid follicles, which are rich in immune cells and can also serve as
sites of induction of immune responses including antibody responses.
However, humoral immunity is more difficult to induce in the female
genital tract,26,27 given that the reproductive tract must maintain the
delicate balance between inhibiting immune responses to spermato-
zoa and fetuses and inducing immunity against foreign microbes. In
fact, most of the immunity present within the reproductive tract is
derived from other mucosal sites, predominately the rectum and Pey-
er’s patches of the GI tract.14,15 If cervical immunity is mostly local and
does not engage systemic humoral immunity, antibody responses to
biologically relevant infections will be muted, consistent with our data.
Furthermore, the penis and vulva are largely keratinized epithelia,
which may further reduce access to the immune system compared
with infections that occur at mucosal surfaces.
The main limitation of this work was that the number of incident
cancers available for study was relatively small, an inherent issue in
studies of rare cancers. Furthermore, subsequent work will involve
identifying tumor material from prospectively detected cases to eval-
uate the sensitivity of the serology assay in detecting truly HPV16-
driven disease, an undertaking well beyond the scope of the current
project. Finally, data on cancer stage were missing in the majority of
patients, and thus, we were unable to evaluate whether antibody pos-
itivity was related to stage at diagnosis.
Our body of work to date within the European population indi-
cates that seropositivity against HPV16 E6 is common in individuals
who later develop OPC, relatively common among those who develop
anal cancers, but rare among those who develop other HPV-related
cancers, including cervical, vulvar, vaginal, and penile cancers. Never-
theless, seropositivity in cervical cancer, by far the most common of all
HPV-related cancers,25 remained significantly elevated versus con-
trols and increased notably the closer in time to diagnosis. Hence,
should the incidence of HPV-related OPC continue increasing to the
extent that it would motivate screening using HPV16 E6 serology
assay,8,28 our results suggest that screening for anal and cervical can-
cers should also be considered in the clinical work-up of patients who
test positive for HPV16 E6, in particular in populations lacking ade-
quate screening for cervical cancer. Future studies in populations with
different HPV prevalence and studies that aim to understand the
preclinical presentation and biologic underpinning of these findings
are warranted and will inform on the potential of HPV16 E6 as a
prediagnostic biomarker for HPV-driven cancers.
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Male 0 0 0 0 3 12.5 5 15.6 24 100 18 100 0 0 0 0 0 0 0 0
Female 273 100 793 100 21 87.5 27 84.4 0 0 0 0 12 100 6 100 67 100 50 100
Age, years
 40 96 35.2 232 29.3 0 0 0 0 0 0 0 0 1 8.3 0 0 2 3.0 0 0
41-50 103 37.7 198 25.0 4 16.7 1 3.1 5 20.8 0 0 0 0 0 0 8 11.9 7 14.0
51-60 55 20.1 222 28.0 7 29.2 16 50.0 4 16.7 7 38.9 4 33.3 3 50.0 9 13.4 13 26.0
61-70 13 4.8 114 14.4 10 41.7 10 31.3 8 33.3 8 44.4 6 50.0 2 33.3 33 49.3 16 32.0
 70 6 2.2 27 3.4 3 12.5 5 15.6 7 29.2 3 16.7 1 8.3 1 16.7 15 22.4 14 28.0
Country
Denmark 0 0 94 11.9 0 0 11 34.4 0 0 10 55.6 0 0 1 16.7 0 0 11 22.0
France 0 0 56 7.1 2 8.3 8 25.0 0 0 0 0 0 0 0 0 1 1.5 10 20.0
Germany 45 16.5 51 6.4 9 37.5 1 3.1 7 29.2 0 0 6 50.0 0 0 12 17.9 0 0
Great Britain 49 17.9 346 43.6 5 20.8 5 15.6 5 20.8 1 5.6 0 0 2 33.3 13 19.4 10 20.0
Greece 10 3.7 15 1.9 0 0 0 0 2 8.3 0 0 1 8.3 0 0 7 10.4 0 0
Italy 18 6.6 34 4.3 3 12.5 0 0 2 8.3 0 0 1 8.3 0 0 7 10.4 1 2.0
The Netherlands 5 1.8 20 2.5 1 4.2 0 0 1 4.2 0 0 1 8.3 0 0 17 25.4 0 0
Norway 2 7.0 40 5.0 0 0 5 15.6 0 0 0 0 1 8.3 1 16.7 2 3.0 5 10.0
Spain 22 8.1 31 3.9 0 0 0 0 4 16.7 0 0 1 8.3 1 16.7 5 7.5 0 0
Sweden 122 44.7 106 13.4 4 16.7 2 6.3 3 12.5 7 38.9 1 8.3 1 16.7 3 4.5 13 26.0
Smoking
Never 127 46.5 352 44.4 12 50.0 11 34.4 8 33.3 4 22.2 10 83.3 1 16.7 36 53.7 22 44.0
Former 59 21.6 195 24.6 6 25.0 11 34.4 8 33.3 7 38.9 1 8.3 1 16.7 14 20.9 12 24.0
Current 83 30.4 242 30.5 4 16.7 9 28.1 8 33.3 7 38.9 1 8.3 4 66.7 17 25.4 16 32.0
Education
Primary 54 19.8 143 18.0 11 45.8 3 9.4 10 41.7 7 38.9 6 50.0 4 66.7 32 47.8 12 24.0
 Primary school 216 79.1 639 80.6 11 45.8 29 90.6 14 58.3 11 61.1 6 50.0 2 33.3 35 52.2 36 72.0
NOTE. The following patients were excluded: patients without available blood samples, patients without baseline questionnaire, and patients from three centers
that did not participate in the current study (Copenhagen, Århus, and Malmö). All remaining patients with noncervical anogenital cancers were included, as were a
subset of the larger number of eligible patients with cervical cancer.
Percentages do not add to 100% as a result of missing data.
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